Expression of PAWR predicts prognosis of ovarian cancer

Ovarian cancer greatly threatens the general health of women worldwide. Implementation of predictive prognostic biomarkers aids in ovarian cancer management. Using online databases, the general expression profile, target-disease associations, and interaction network of PAWR were explored. To identif...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international 2020-12, Vol.20 (1), p.598-598, Article 598
Main Authors: Tan, Jiahong, Tao, Kangjia, Zheng, Xu, Liu, Dan, Ma, Ding, Gao, Qinglei
Format: Article
Language:English
Subjects:
Apoptosis
Biomarkers
Breast cancer
Cancer therapies
Chemotherapy
Correlation analysis
Disease
Drug responsiveness
Fallopian tubes
Gene expression
Genomics
Gynecology
Medical prognosis
Mutation
Ovarian cancer
Paclitaxel
PAWR
Platinum
Primary Research
Protein expression
Proteins
Survival
Survival analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c597t-4226842ed43931e13981f298629081a0f8ddaa152ce41684be1d2b11e4d4b3d43
cites cdi_FETCH-LOGICAL-c597t-4226842ed43931e13981f298629081a0f8ddaa152ce41684be1d2b11e4d4b3d43
container_end_page 598
container_issue 1
container_start_page 598
container_title Cancer cell international
container_volume 20
creator Tan, Jiahong
Tao, Kangjia
Zheng, Xu
Liu, Dan
Ma, Ding
Gao, Qinglei
description Ovarian cancer greatly threatens the general health of women worldwide. Implementation of predictive prognostic biomarkers aids in ovarian cancer management. Using online databases, the general expression profile, target-disease associations, and interaction network of PAWR were explored. To identify the role of PAWR in ovarian cancer, gene correlation analysis, survival analysis, and combined analysis of drug responsiveness and PAWR expression were performed. The predictive prognostic value of PAWR was further validated in clinical samples. PAWR was widely expressed in normal and cancer tissues, with decreased expression in ovarian cancer tissues compared with normal tissues. PAWR was associated with various cancers including ovarian cancer. PAWR formed a regulatory network with a group of proteins and correlated with several genes, which were both implicated in ovarian cancer and drug responsiveness. High PAWR expression denoted better survival in ovarian cancer patients (OS: HR = 0.84, P = 0.0077; PFS, HR = 0.86, P = 0.049). Expression of PAWR could predict platinum responsiveness in ovarian cancer and there was a positive correlation between PAWR gene effect and paclitaxel sensitivity. In 12 paired clinical samples, the cancerous tissues exhibited significantly lower PAWR expression than matched normal fallopian tubes. The predictive prognostic value of PAWR was maintained in a cohort of 50 ovarian cancer patients. High PAWR expression indicated better survival and higher drug responsiveness in ovarian cancer patients. PAWR could be exploited as a predictive prognostic biomarker in ovarian cancer.
doi_str_mv 10.1186/s12935-020-01704-y
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d5b4f2bf426c4ba2b0dd15b875e74a4f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d5b4f2bf426c4ba2b0dd15b875e74a4f</doaj_id><sourcerecordid>2471206998</sourcerecordid><originalsourceid>FETCH-LOGICAL-c597t-4226842ed43931e13981f298629081a0f8ddaa152ce41684be1d2b11e4d4b3d43</originalsourceid><addsrcrecordid>eNpdkV1rVDEQhoMo9kP_gBey4I03RzOT5CS5EUqptVBQRPEy5OusWc6erMnZ0v33Zru1tF5lmHnmIclLyBugHwBU_7ECaiY6irSjICnvds_IMXApOlS9fP6oPiInta5oo1RPX5IjxhhIIeCYyIvbTYm1pjwt8rD4dvbr-6I1QvJzbUVeTrmmuh_lG1uSnRbeTj6WV-TFYMcaX9-fp-Tn54sf51-666-XV-dn150XWs4dR-wVxxg40wwiMK1gQK161FSBpYMKwVoQ6COHRroIAR1A5IE71rZOydXBG7JdmU1Ja1t2Jttk7hq5LI0tc_JjNEE4PqAbOPaeO4uOhgDCKSmi5JYPzfXp4Nps3ToGH6e52PGJ9OlkSr_NMt8YKZlkXDTB-3tByX-2sc5mnaqP42inmLfVIJcUpWY9NPTdf-gqb8vUvmpPAdJea9UoPFC-5FpLHB4uA9TsMzaHjE3L2NxlbHZt6e3jZzys_AuV_QVKjqE0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471206998</pqid></control><display><type>article</type><title>Expression of PAWR predicts prognosis of ovarian cancer</title><source>PubMed Central Free</source><source>Publicly Available Content (ProQuest)</source><creator>Tan, Jiahong ; Tao, Kangjia ; Zheng, Xu ; Liu, Dan ; Ma, Ding ; Gao, Qinglei</creator><creatorcontrib>Tan, Jiahong ; Tao, Kangjia ; Zheng, Xu ; Liu, Dan ; Ma, Ding ; Gao, Qinglei</creatorcontrib><description>Ovarian cancer greatly threatens the general health of women worldwide. Implementation of predictive prognostic biomarkers aids in ovarian cancer management. Using online databases, the general expression profile, target-disease associations, and interaction network of PAWR were explored. To identify the role of PAWR in ovarian cancer, gene correlation analysis, survival analysis, and combined analysis of drug responsiveness and PAWR expression were performed. The predictive prognostic value of PAWR was further validated in clinical samples. PAWR was widely expressed in normal and cancer tissues, with decreased expression in ovarian cancer tissues compared with normal tissues. PAWR was associated with various cancers including ovarian cancer. PAWR formed a regulatory network with a group of proteins and correlated with several genes, which were both implicated in ovarian cancer and drug responsiveness. High PAWR expression denoted better survival in ovarian cancer patients (OS: HR = 0.84, P = 0.0077; PFS, HR = 0.86, P = 0.049). Expression of PAWR could predict platinum responsiveness in ovarian cancer and there was a positive correlation between PAWR gene effect and paclitaxel sensitivity. In 12 paired clinical samples, the cancerous tissues exhibited significantly lower PAWR expression than matched normal fallopian tubes. The predictive prognostic value of PAWR was maintained in a cohort of 50 ovarian cancer patients. High PAWR expression indicated better survival and higher drug responsiveness in ovarian cancer patients. PAWR could be exploited as a predictive prognostic biomarker in ovarian cancer.</description><identifier>ISSN: 1475-2867</identifier><identifier>EISSN: 1475-2867</identifier><identifier>DOI: 10.1186/s12935-020-01704-y</identifier><identifier>PMID: 33317551</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Apoptosis ; Biomarkers ; Breast cancer ; Cancer therapies ; Chemotherapy ; Correlation analysis ; Disease ; Drug responsiveness ; Fallopian tubes ; Gene expression ; Genomics ; Gynecology ; Medical prognosis ; Mutation ; Ovarian cancer ; Paclitaxel ; PAWR ; Platinum ; Primary Research ; Protein expression ; Proteins ; Survival ; Survival analysis</subject><ispartof>Cancer cell international, 2020-12, Vol.20 (1), p.598-598, Article 598</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c597t-4226842ed43931e13981f298629081a0f8ddaa152ce41684be1d2b11e4d4b3d43</citedby><cites>FETCH-LOGICAL-c597t-4226842ed43931e13981f298629081a0f8ddaa152ce41684be1d2b11e4d4b3d43</cites><orcidid>0000-0002-9448-3423</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737345/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2471206998?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33317551$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tan, Jiahong</creatorcontrib><creatorcontrib>Tao, Kangjia</creatorcontrib><creatorcontrib>Zheng, Xu</creatorcontrib><creatorcontrib>Liu, Dan</creatorcontrib><creatorcontrib>Ma, Ding</creatorcontrib><creatorcontrib>Gao, Qinglei</creatorcontrib><title>Expression of PAWR predicts prognosis of ovarian cancer</title><title>Cancer cell international</title><addtitle>Cancer Cell Int</addtitle><description>Ovarian cancer greatly threatens the general health of women worldwide. Implementation of predictive prognostic biomarkers aids in ovarian cancer management. Using online databases, the general expression profile, target-disease associations, and interaction network of PAWR were explored. To identify the role of PAWR in ovarian cancer, gene correlation analysis, survival analysis, and combined analysis of drug responsiveness and PAWR expression were performed. The predictive prognostic value of PAWR was further validated in clinical samples. PAWR was widely expressed in normal and cancer tissues, with decreased expression in ovarian cancer tissues compared with normal tissues. PAWR was associated with various cancers including ovarian cancer. PAWR formed a regulatory network with a group of proteins and correlated with several genes, which were both implicated in ovarian cancer and drug responsiveness. High PAWR expression denoted better survival in ovarian cancer patients (OS: HR = 0.84, P = 0.0077; PFS, HR = 0.86, P = 0.049). Expression of PAWR could predict platinum responsiveness in ovarian cancer and there was a positive correlation between PAWR gene effect and paclitaxel sensitivity. In 12 paired clinical samples, the cancerous tissues exhibited significantly lower PAWR expression than matched normal fallopian tubes. The predictive prognostic value of PAWR was maintained in a cohort of 50 ovarian cancer patients. High PAWR expression indicated better survival and higher drug responsiveness in ovarian cancer patients. PAWR could be exploited as a predictive prognostic biomarker in ovarian cancer.</description><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Correlation analysis</subject><subject>Disease</subject><subject>Drug responsiveness</subject><subject>Fallopian tubes</subject><subject>Gene expression</subject><subject>Genomics</subject><subject>Gynecology</subject><subject>Medical prognosis</subject><subject>Mutation</subject><subject>Ovarian cancer</subject><subject>Paclitaxel</subject><subject>PAWR</subject><subject>Platinum</subject><subject>Primary Research</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>Survival</subject><subject>Survival analysis</subject><issn>1475-2867</issn><issn>1475-2867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkV1rVDEQhoMo9kP_gBey4I03RzOT5CS5EUqptVBQRPEy5OusWc6erMnZ0v33Zru1tF5lmHnmIclLyBugHwBU_7ECaiY6irSjICnvds_IMXApOlS9fP6oPiInta5oo1RPX5IjxhhIIeCYyIvbTYm1pjwt8rD4dvbr-6I1QvJzbUVeTrmmuh_lG1uSnRbeTj6WV-TFYMcaX9-fp-Tn54sf51-666-XV-dn150XWs4dR-wVxxg40wwiMK1gQK161FSBpYMKwVoQ6COHRroIAR1A5IE71rZOydXBG7JdmU1Ja1t2Jttk7hq5LI0tc_JjNEE4PqAbOPaeO4uOhgDCKSmi5JYPzfXp4Nps3ToGH6e52PGJ9OlkSr_NMt8YKZlkXDTB-3tByX-2sc5mnaqP42inmLfVIJcUpWY9NPTdf-gqb8vUvmpPAdJea9UoPFC-5FpLHB4uA9TsMzaHjE3L2NxlbHZt6e3jZzys_AuV_QVKjqE0</recordid><startdate>20201214</startdate><enddate>20201214</enddate><creator>Tan, Jiahong</creator><creator>Tao, Kangjia</creator><creator>Zheng, Xu</creator><creator>Liu, Dan</creator><creator>Ma, Ding</creator><creator>Gao, Qinglei</creator><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9448-3423</orcidid></search><sort><creationdate>20201214</creationdate><title>Expression of PAWR predicts prognosis of ovarian cancer</title><author>Tan, Jiahong ; Tao, Kangjia ; Zheng, Xu ; Liu, Dan ; Ma, Ding ; Gao, Qinglei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c597t-4226842ed43931e13981f298629081a0f8ddaa152ce41684be1d2b11e4d4b3d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Correlation analysis</topic><topic>Disease</topic><topic>Drug responsiveness</topic><topic>Fallopian tubes</topic><topic>Gene expression</topic><topic>Genomics</topic><topic>Gynecology</topic><topic>Medical prognosis</topic><topic>Mutation</topic><topic>Ovarian cancer</topic><topic>Paclitaxel</topic><topic>PAWR</topic><topic>Platinum</topic><topic>Primary Research</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>Survival</topic><topic>Survival analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tan, Jiahong</creatorcontrib><creatorcontrib>Tao, Kangjia</creatorcontrib><creatorcontrib>Zheng, Xu</creatorcontrib><creatorcontrib>Liu, Dan</creatorcontrib><creatorcontrib>Ma, Ding</creatorcontrib><creatorcontrib>Gao, Qinglei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>PHMC-Proquest健康医学期刊库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cancer cell international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tan, Jiahong</au><au>Tao, Kangjia</au><au>Zheng, Xu</au><au>Liu, Dan</au><au>Ma, Ding</au><au>Gao, Qinglei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of PAWR predicts prognosis of ovarian cancer</atitle><jtitle>Cancer cell international</jtitle><addtitle>Cancer Cell Int</addtitle><date>2020-12-14</date><risdate>2020</risdate><volume>20</volume><issue>1</issue><spage>598</spage><epage>598</epage><pages>598-598</pages><artnum>598</artnum><issn>1475-2867</issn><eissn>1475-2867</eissn><abstract>Ovarian cancer greatly threatens the general health of women worldwide. Implementation of predictive prognostic biomarkers aids in ovarian cancer management. Using online databases, the general expression profile, target-disease associations, and interaction network of PAWR were explored. To identify the role of PAWR in ovarian cancer, gene correlation analysis, survival analysis, and combined analysis of drug responsiveness and PAWR expression were performed. The predictive prognostic value of PAWR was further validated in clinical samples. PAWR was widely expressed in normal and cancer tissues, with decreased expression in ovarian cancer tissues compared with normal tissues. PAWR was associated with various cancers including ovarian cancer. PAWR formed a regulatory network with a group of proteins and correlated with several genes, which were both implicated in ovarian cancer and drug responsiveness. High PAWR expression denoted better survival in ovarian cancer patients (OS: HR = 0.84, P = 0.0077; PFS, HR = 0.86, P = 0.049). Expression of PAWR could predict platinum responsiveness in ovarian cancer and there was a positive correlation between PAWR gene effect and paclitaxel sensitivity. In 12 paired clinical samples, the cancerous tissues exhibited significantly lower PAWR expression than matched normal fallopian tubes. The predictive prognostic value of PAWR was maintained in a cohort of 50 ovarian cancer patients. High PAWR expression indicated better survival and higher drug responsiveness in ovarian cancer patients. PAWR could be exploited as a predictive prognostic biomarker in ovarian cancer.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>33317551</pmid><doi>10.1186/s12935-020-01704-y</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-9448-3423</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1475-2867
ispartof Cancer cell international, 2020-12, Vol.20 (1), p.598-598, Article 598
issn 1475-2867
1475-2867
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d5b4f2bf426c4ba2b0dd15b875e74a4f
source PubMed Central Free; Publicly Available Content (ProQuest)
subjects Apoptosis
Biomarkers
Breast cancer
Cancer therapies
Chemotherapy
Correlation analysis
Disease
Drug responsiveness
Fallopian tubes
Gene expression
Genomics
Gynecology
Medical prognosis
Mutation
Ovarian cancer
Paclitaxel
PAWR
Platinum
Primary Research
Protein expression
Proteins
Survival
Survival analysis
title Expression of PAWR predicts prognosis of ovarian cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A13%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20PAWR%20predicts%20prognosis%20of%20ovarian%20cancer&rft.jtitle=Cancer%20cell%20international&rft.au=Tan,%20Jiahong&rft.date=2020-12-14&rft.volume=20&rft.issue=1&rft.spage=598&rft.epage=598&rft.pages=598-598&rft.artnum=598&rft.issn=1475-2867&rft.eissn=1475-2867&rft_id=info:doi/10.1186/s12935-020-01704-y&rft_dat=%3Cproquest_doaj_%3E2471206998%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c597t-4226842ed43931e13981f298629081a0f8ddaa152ce41684be1d2b11e4d4b3d43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2471206998&rft_id=info:pmid/33317551&rfr_iscdi=true